Trials / Completed
CompletedNCT02189629
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 453 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
Detailed description
To determine the safety and efficacy of CD5789 (trifarotene) 50 µg/g cream in the long-term treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a secondary objective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD5789 (trifarotene) |
Timeline
- Start date
- 2015-02-23
- Primary completion
- 2017-02-23
- Completion
- 2017-02-23
- First posted
- 2014-07-14
- Last updated
- 2019-11-14
- Results posted
- 2019-09-17
Locations
32 sites across 4 countries: United States, Czechia, Germany, Hungary
Source: ClinicalTrials.gov record NCT02189629. Inclusion in this directory is not an endorsement.